The Report Inn, Author at The Report Inn

The actress, who was recently diagnosed with Myositis, announced her return to work on social media. She posted a photo...

The Central Bureau of Investigation (CBI) in Nellore has stepped up its investigation into the theft of documents from the city's IV Additional Judicial First Class Magistrate Court that were related to a case involving Agriculture Minister Kakani Govardhan Reddy. The complainant in the case, prominent TDP politician Somireddy Chandramohan Reddy, was interviewed by CBI agents while they were in Nellore. A few more people's comments about this case will probably be recorded by the CBI. Speaking to the media on Friday, Somireddy said that CBI agents Nirmala Devi and Ananthakrishnan interrogated him for more than 1.5 hours and instructed him to file a formal complaint the next week. He hoped that the offenders would receive the worst sentence possible for stealing evidence from the Delhi Uphaar tragedy. "Kakani had fabricated documents to show that I had accumulated significant wealth by tarnishing the reputation of my family. In the Nellore court complex, which consists of 17 courts, there are more than 15,000 case files. The evidence that was presented to the court in relation to them disappeared, according to Somireddy. You might remember that Kakani claimed Somireddy had accumulated a sizable fortune through unethical means. In December 2017, he released a few papers in an effort to substantiate the claim. In response to the accusation, Somireddy filed a police report alleging that the papers made public by Kakani were fake. A chargesheet was also submitted in response to his allegation. On April 14, 2022, not long after Kakani was sworn in as a minister, the evidence that was provided to the court in the case was stolen. The thieves took a bag that included papers, stamps, and technological equipment. The Nellore police opened an investigation when the court employees submitted a complaint. The AP High Court ordered the CBI to look into the theft case in November 2022.

Andhra Pradesh

CBI Expands its Investigation into the Nellore Court Heist Case

The Central Bureau of Investigation (CBI) in Nellore has stepped up its investigation into the theft of documents from the...

Andhra Pradesh

Official’s Andhra Pradesh Explanation for Skipping Court Revealed

The judge instructed the court registry to suo motu file a contempt of court against Rao because she viewed his...

A Prakash, A Srinu, V Nagaraju, K Naga Sreenu, and A Pothu Raju were named as the defendants. GUNTUR: Five criminals were taken into custody on Friday after being suspected of a significant burglary. Additionally, the Palanadu police found Rs. 10 lakh in their custody. SP Ravishankar Reddy revealed the specifics, stating that on August 17, 2022, an unauthorised intruder entered into the home of P Sambaiah, the proprietor of a nursery in Rajupalem village, and stole Rs 17 lakh, along with mobile phones. Police at Rajupalem launched an inquiry after receiving a complaint. A Prakash, A Srinu, V Nagaraju, K Naga Sreenu, and A Pothu Raju were named as the defendants. The primary suspect, Prakash, entered Sambaiah's home at midnight, while the other three suspects remained outside to keep an eye on the residence. As Prakash was collecting money from the locker, a couple who was sound asleep in the adjacent room heard a commotion and went to investigate. When Prakash saw the couple in the room, he tried to leave by threatening them with a knife, but they locked him in and told the police about it. When the police showed up, they discovered that Prakash had gotten out of the washroom through the window. The SP also disclosed that the defendants had been arrested in related instances at several police stations in the former Guntur district.

Andhra Pradesh

Five are Detained in Connection with a Break-In, and $10,000 is Found in Cash

A Prakash, A Srinu, V Nagaraju, K Naga Sreenu, and A Pothu Raju were named as the defendants. GUNTUR: Five...

Education

At MLRIT, an Awareness Programme on Incubation and Networking Was Held

Students presented ideas and prototypes to Ramjee Pallela and Atal Incubation Centre board members. On Friday, the Centre for Innovation...

Education

There are 1,11,209 Candidates Who Have Qualified for The TSLPRB Final Written Examinations

The PMT/PET for a total of 2,07,106 candidates was successfully completed on January 5 at various venues in 12 locations...

Education

Sri Chaitanya School sets a new world record by presenting 100 math tables in 100 minutes

Sri Chaitanya School set a world record for the fastest presentation of math tables from 1 to 100 in 100...

Andhra Pradesh

Farmers Worry the Lumpy Virus may Spread After 10 Animals Die

However, officials assuage concerns by stating that "Allergic Dermatitis" is the cause of the cattle's poor health in the western...

Dementia, a series of illnesses that alter how a person's brain functions, affects more than 55 million individuals worldwide. Alzheimer's disease is the cause of between 60% and 80% of all dementia cases. By 2050, researchers estimate that there will be over 153 million individuals worldwide living with dementia. Alzheimer's disease presently has no known treatment. However, a small number of FDA-approved medications for Alzheimer's disease are intended to either delay the illness's progression or assist treat some of its symptoms. Additional possible therapies, such lecanemab, are now being studied. Lecanemab was given fast approval by the U.S. Food and Drug Administration (FDA) for use in treating persons with early-stage Alzheimer’s disease. According to Dr. Billy Dunn, head of the Office of Neuroscience at the FDA's Center for Drug Evaluation and Research, "Alzheimer's disease irreparably impairs the lives of individuals who suffer from it and has terrible impacts on their loved ones." This alternative for treatment is the most recent therapy to target and influence the underlying disease process of Alzheimer's disease rather than only treating the illness's symptoms. Three deaths were reportedly reported to have happened during the drug's clinical testing when the approval was being given. Describe lecanemab. Lecanemab is an experimental medication being researched by Eisai and Biogen for the treatment of Alzheimer's disease. Lecanemab belongs to a class of medication known as a monoclonal antibodyTrusted Source. Antibodies are made by the human body spontaneously to protect against infection. To combat a specific foreign substance in the body known as an antigen, scientists develop monoclonal antibodies in a lab setting. The monoclonal antibody induces the immune system to eliminate the specific antigen when it is put into a person's body. Recently, medical professionals have employed monoclonal antibodies to treat COVID-19 and certain malignancies. Lecanemab targets the amyloid protein. Dr. Christopher H. van Dyck, professor of psychiatry, neurology, and neuroscience, director of the Yale Alzheimer's Disease Research Center, director of the Division of Aging and Geriatric Psychiatry, and director of the Alzheimer's Disease Research Unit, explained for Medical News Today as a Trusted Source. The New England Journal of Medicine article on Eisai's Phase 3 confirmatory Clarity AD clinical trial of lecanemab has a paper on which Dr. van Dyck is the principal author. According to him, "the goal is that it will inhibit the aetiology of Alzheimer's disease and halt the clinical course of the disease."

Health

Why a New Alzheimer’s Medication, Lecanemab, has Garnered Acclaim and Some Trepidation